CTLA4 and melanoma: As shown in Figure 6A, melanoma patients who responded to adoptive T-cell therapy (ACT) treatment (GSE35640), anti-PD-1 (PUCH, Gide19, and Liu19 cohorts) or anti-CTLA-4 (VanAllen15 cohort) showed a significant lower ICDscore than those who were non-responders to immunotherapies.